# A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

Source: https://onco.cc/trials/nct06980480/  
OnCo record `nct06980480` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of IGI, 10% in multiple myeloma, run by Takeda, now recruiting.

## Summary

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma is a phase 3 interventional study registered as NCT06980480 by Takeda, with 183 participants planned, started 2026-01-14 and due to reach its primary completion in 2028-09-11. Interventions recorded: IGI, 10%.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06980480
- Phase: 3
- Setting: A Multicenter, Randomized, Controlled, Open-label, Group-Sequential, Phase 3 Study to Investigate the Efficacy, Safety, and Tolerability of Intravenous Gammagard Liquid (Immune Globulin Infusion, 10%) for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Adult Subjects With Multiple Myeloma Receiving B-Cell Maturation AntigenxCD3-Directed Bispecific Antibody Therapy
- Sponsor: Takeda
- Enrolled: 183

## Sources

- ClinicalTrials.gov NCT06980480: https://clinicaltrials.gov/study/NCT06980480

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- companies: [Takeda](https://onco.cc/companies/takeda/)

---
JSON: https://onco.cc/api/v1/entities/nct06980480.json